A cochlea and hairs
As superbugs rise in incidence, scientists are scrambling to find new anti-infective drugs to combat these hardy microbes. Seattle startup Oricula Therapeutics is developing a drug that could help bring a line of antibiotics, called aminoglycosides, into broader use.
Aminoglycosides are powerful drugs used primary for serious Gram-negative bacterial infections – with use in treating septicemia, E. Coli and a number of other hard-to-control conditions. However, they are used very sparingly because they carry a high risk of causing auditory toxicity – hearing loss or even deafness – in patients.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Oricula Therapeutics’ aim is to protect the inner ear from damage caused by antibiotic use. In animal models, Oricula says its drug protects the delicate hair cells within the ear from antibiotic-related death.
The company just received a $2 million NIH grant to wrap up preclinical work for its lead compound, ORC-13661. This round will help with safety and toxicology testing to allow for an IND to be filed, and Phase 1 testing to begin.
“Now that the preclinical workup is assured, I’m spending much of my time designing the ideal first-in-human proof-of-concept clinical trials for our lead compound,” Oricula CEO Malcolm Gleser said in a statement.
[Image courtesy of Flickr user eLife]
